tirzepatide study flags need to monitor frailty risks with GLP-1 drugs for older adults SURMOUNT‐1 study design. This is

However, clinical studies consistently demonstrate substantial reductions in waist circumference and visceral adipose tissue volume, suggesting that abdominal fat responds as part of generalized fat loss with these medications

Nausea is among the most commonly reported adverse events in Phase 2 trial data, occurring most frequently during dose escalation and at higher doses

GLP-1, PYY and other hormones spike after surgery improving insulin sensitivity and reducing the livers cholesterol output

Sex was determined using the biological information recorded in patient medical charts

Home offices reflected the digital economy shaped by COVID